Physician profile
Timothy C Chen
NPI 1073830790
$5,943.26
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,070 · 2020: $2,281 · 2021: $1,504 · 2022: $44.38 · 2023: $21.86 · 2024: $22.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $926.18 | 2019-2021 | |
| Pfizer INC. | $598.66 | 2019-2021 | |
| Lilly USA, LLC | $554.88 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $468.35 | 2019-2022 | |
| Allergan, INC. | $465.93 | 2019-2020 | |
| Abbvie INC. | $298.05 | 2020-2021 | |
| Amgen INC. | $281.55 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $278.20 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.75 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.78 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $216.13 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $197.69 | 2019-2021 | |
| Astellas Pharma US INC | $178.08 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.12 | 2019-2021 | |
| Novo Nordisk INC | $110.56 | 2020-2024 | Wegovy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $102.56 | 2019-2021 | |
| Genentech USA, INC. | $90.59 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $84.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $74.10 | 2019 | |
| Amarin Pharma, INC. | $68.51 | 2019-2021 | |
| Gilead Sciences, INC. | $47.89 | 2019-2020 | |
| Abbott Laboratories | $44.46 | 2019 | |
| Shire North American Group INC | $42.51 | 2019 | |
| Esperion Therapeutics, INC. | $41.84 | 2020-2021 | |
| Dexcom, INC. | $24.61 | 2021 | |
| Upsher-Smith Laboratories LLC | $19.44 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.48 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.59 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.34 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $13.17 | 2019 | |
| Melinta Therapeutics, LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.